Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer.

CONCLUSIONS: Among patients with mTNBC treated with anti-PD-1/L1 therapies, high TMB and PTEN alterations were associated with longer and shorter survival, respectively. These observations warrant validation in larger datasets.
PMID: 32019858 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 3, 2020 Category: Cancer & Oncology Authors: Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes ME, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop I, Dillon DA, Winer EP, Wagle N, Lin NU, Mittendorf EA, Van Allen EM, Tolaney SM Tags: Clin Cancer Res Source Type: research